Kornimate/medical-research-clean huggingface dataset:
stroke prevention in atrial fibrillation patients between 2004 and 2020

Conditions: Atrial Fibrillation; Stroke Prevention

Summary: prevention of thromboembolic complications is an important part in the management of patients with atrial fibrillation (af). european and american guidelines recommend the use of non-vitamin k antagonist oral anticoagulants (noacs) over therapy with vitamin k antagonists (vka) in most af patients. the number of patients treated with noacs has increased significantly during the last few years. in the primary randomized controlled trials leading to their approval, compared to warfarin, noacs were shown to be either noninferior or superior for stroke prevention in af, with similar or reduced rates of bleeding, especially intracranial haemorrhage. the aim of this study was to assess the frequency of oral anticoagulants using, espescially apixaban, dabigatran, and rivaroxaban, and the predictors of their prescription in a group of hospitalised patients with af.


Eligibility criteria:
inclusion criteria: - non-valvular atrial fibrillation exclusion criteria: * valvular atrial fibrillation * death during hospitalization
nephrogenic systemic fibrosis with gadollinum

Conditions: Nephrogenic Systemic Fibrosis; Renal Failure

Summary: recently there is increasing reports of nephrogeniic systemic fibrosis(nsf) in patients with severe renal failure mainly in patients under dialysis in whom gadollinum is being used. the investigators will evaluate the prevalence and severity of nsf in patients with different degree of renal failure whom underwent imaging with gadolinum.

nsf is a progressive and potentially fatal disease reported mainly in end stage renal disease (esrd) patients in whom gadolinume been used as contrast agent. skin is the main organ of involvement but other vital organs like myocard,lung,liver may also be involved.gadollinum is known as a safe contrast in renal disease patients in comparison with conventional nephrotoxic radiocontrast agents,but with increasing reports of nsf with gadollinum the use of this agent in renal failure patients is under question. we will retrospectively evaluate the occurrence of this complication in all patients with different degree of renal failure whom underwent mra or mri with gadollinum in tehran heart center since 2003 till now and we will describe the severity and distribution pattern of lesions and the relation of this complication to the severity of renal failure.

Eligibility criteria:
inclusion criteria: * renal failure * use of gadollinum exclusion criteria: * no consent * age under 18

Keywords: nsf esrd mra mri occurrence of nsf use of gadollinum
have physical therapists attitudes and beliefs towards vital assessment changed following the covid-19 pandemic?

Conditions: Vital Signs

Summary: previous studies prior to the covid-19 pandemic show that cardiovascular and blood pressure assessment by physical therapists is inadequate or lacking despite prior training. since the covid-19 pandemic, assessment of cardiovascular and respiratory function may become more critical as the manifestation of long covid has become a concern. the purpose of this study is to determine whether physical therapists' attitudes and beliefs towards vital sign assessment have changed following the covid-19 pandemic.


Eligibility criteria:
inclusion criteria: 1. must be a licensed physical therapist 2. must be actively be involved in clinical practice 3. must have ≥ 5 years of experience practicing in a clinical setting as a physical therapist exclusion criteria: (1) did not provide informed consent

Keywords: vital sign physical therapy assessment covid-19
imaging study to investigate safety and diagnostic performance of 18f rhpsma 7.3 pet ligand in suspected prostate cancer recurrence

Conditions: Prostate Cancer

Summary: a prospective, phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhpsma 7.3 (18f) positron emission tomography (pet) ligand in men with suspected prostate cancer recurrence based on elevated prostate-specific antigen (psa) following prior therapy.

the primary objective of this study was to assess the patient-level correct detection rate (cdr) and region-level positive predictive value (ppv) of rhpsma-7.3 (18f) positron emission tomography (pet) for biochemical recurrence (bcr) of prostate cancer using histopathology or imaging as a standard of truth (sot).

Eligibility criteria:
inclusion criteria: 1. patient is male and aged \>18 years old. 2. history of localized adenocarcinoma of the prostate with prior curative intent treatment. 3. an elevated psa, clinically suspicious for biochemically recurrent disease: * following radical prostatectomy: psa \>0.2 ng/ml * following radiotherapy: nadir +2 ng/ml. 4. potentially eligible for salvage therapy with curative intent. exclusion criteria: 1. patients who are planned to have an x-ray contrast agent or other pet radiotracer \<24 hours prior to the pet scan. 2. patients currently receiving androgen deprivation therapy (adt).

Keywords: recurrent prostate cancer diagnostic prostate specific membrane antigen (psma) positron emission tomography (pet) scan
a study of ql1706 in combination with chemotherapy in pd-l1-negative non-small cell lung cancer

Conditions: Lung Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of ql1706 combined with platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy in pd-l1 negative, locally advanced or metastatic non-small cell lung cancer patients. the subjects were randomly divided into two groups according to 1:1, with about 304 subjects in the experimental group and the control group.

this study was a randomized, double-blind, active-controlled, multicenter phase 3 clinical study. the study is designed to evaluate the efficacy and safety of ql1706 in combination with chemotherapy or commercial pd1 in combination with chemotherapy in locally advanced or metastatic nsclc patients who are pd-l1 negative.608 patients would be enrolled . subjects will be assigned randomly in a 1:1 ratio to experimental group and control group. subjects will be stratified by pathological type: squamous cell carcinoma versus non-squamous cell carcinoma; brain metastasis: present versus absent; gender: male versus female. after randomization, subjects will be treated according to the randomization results.

Eligibility criteria:
inclusion criteria: 1. be≥18 to ≤ 75 years of age at enrollment, male or female. 2. histologically or cytologically confirmed locally advanced (stage iiib/iiic) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (stage iv) nsclc (american joint committee on cancer \[ajcc\] 8th edition). 3. no egfr sensitive mutations or alk gene translocation alterations. 4. capable of providing fresh or archived 2 years' tissue samples collected at post-diagnosis or non-radiation sites at diagnosis for central laboratory pd-l1 testing with tps \< 1% . 5. have a life expectancy of at least 3 months. 6. eastern cooperative oncology group (ecog) performance status of 0 or 1. 7. no prior systemic therapy for advanced or metastatic nsclc was received. exclusion criteria: 1. previous treatment with immune checkpoint inhibitors (pd-1/pd-l1 drugs or drugs acting on another t cell receptor (e.g., ctla-4 etc.), as well as immune checkpoint agonistic antibodies (e.g., anti icos , cd40 , cd137 , gitr , ox40 antibodies, etc.), and immune cell therapy. 2. patients who have received systemic corticosteroids or other immunosuppressive drugs within 2 weeks prior to the first dose. 3. presence or history of any active autoimmune disease, including, but not limited to: autoimmune hepatitis, interstitial pneumonia, pulmonary fibrosis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism. 4. pulmonary radiation therapy \> 30 gy within 6 months prior to first dose; 5. palliative radiotherapy completed 7 days prior to first dose. 6. known or symptomatic active central nervous system (cns) metastases or carcinomatous meningitis during screening. 7. clinically significant cardiovascular or cerebrovascular disease -
an efficacy and safety study of srm003 in the treatment of subjects undergoing creation of an arteriovenous fistula to facilitate hemodialysis access

Conditions: Arteriovenous Fistula

Summary: a study to evaluate the efficacy of srm003 treatment versus participating sites' standard practice treatment in improving the rate of avf maturation and use in subjects with end-stage renal disease undergoing surgery for creation of an avf to facilitate hemodialysis access. it is hypothesized that when placed outside the blood vessel, the seeded srm003 gelatin matrix containing endothelial cells can provide a continuous supply of multiple growth regulatory compounds to the underlying cells within the blood vessel, while being protected from the effects of blood flow in the vessel(s) or complications resulting from being in direct contact with the point of injury.


Eligibility criteria:
inclusion criteria: 1. subject must be 18 years of age or older at the time of signing and dating informed consent (no upper age limit), can be male or female. 2. subject who is of child bearing potential must agree to use adequate contraception for 6 months after randomization. 3. subject must be currently undergoing hemodialysis or anticipating the start of hemodialysis and must require a new permanent, suitable access for the avf creation in the upper extremity. 4. subject must have a life expectancy of at least 26 weeks after randomization. 5. subject must be able to understand and be willing to complete all study requirements. exclusion criteria: 1. subject is currently on an active organ transplant list from a deceased donor or is undergoing assessment and expects to be placed on the active organ or bone marrow transplant list within the next 26 weeks from surgery, or expects to receive a living donor organ or bone marrow within the next 26 weeks and is unwilling to change transplant list status to "hold" for 3 months after randomization. 2. subject has had more than 1 access placement surgery (defined as a new access, not a revision) in the target limb. 3. subject has medical conditions and diseases that may cause non-compliance with the protocol 4. subject has a known allergy to bovine/porcine products or collagen/gelatin products. 5. subject has a history of intravenous drug use within 6 months prior to screening 6. subject is morbidly obese, defined as having a body mass index \>40. 7. pregnant or nursing woman, or plans to become pregnant during the study.

Keywords: arteriovenous fistula surgery vascular injury hemodialysis access
predictors for postoperative delirium after cardiac surgery in adults: a one-year, single center, observational cohort study

Conditions: Postoperative Delirium

Summary: the diagnostic and statistical manual of mental disorders, 5th ed. (dsm-5) describes delirium as a "disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment)". in addition, a "disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception)" occurs. postoperative delirium (pod) usually develops in connection with a surgical procedure within the first five days after an intervention. roughly 10-70% of all surgical patients above the age of 65 years are affected. pod places not only a burden to the patient and their families by increasing functional and cognitive damages, and increasing mortality, it also has a high impact on the health care resource utilization. a patient with pod often requires more intensive care, has a longer length of hospital stay, more complications, and often requires long-term care after being discharged from the hospital. all these aspects show the need for prevention of pod. there are various preoperative risk factors that influence the development of pod. broad research has been done on this topic and shown that advanced age, cognitive impairment, depression and other psychopathologic symptoms, intake of psychotropic substances, sensory impairment like decrease in visual or auditory perception, impairment in daily life activities, dehydration, malnutrition, metabolic dysfunctions, urinary catheters, severity of disease and different comorbidities, such as chronic cardiac insufficiency, atrial fibrillation, or previous history of stroke or infections may favor the occurrence of pod. the incidence of pod is among the highest in cardiac surgery. the study was designed to assess predictors for pod after cardiac surgery. study hypothesis is that some patient variables, scores and biomarkers are not only predictive of the incidence of pod but also of the severity of delirium-associated symptoms and duration of pod after cardiac surgery.


Eligibility criteria:
inclusion criteria: all patients who underwent cardiac surgery with cardiopulmonary bypass at university hospital basel in 2013 were included. exclusion criteria: * patients who died during the operation. * patients who lack the primary outcome measure.

Keywords: postoperative delirium cardiac surgery cardiopulmonary bypass risk factor
comparison of the efficacy of conventional landmark, ultrasound-assisted, and real-time ultrasound-guided techniques in spinal anesthesia for obese patients

Conditions: Spinal Anesthesia; Ultrasound

Summary: spinal anesthesia is frequently administered using the conventional landmark technique. ultrasound is a non-invasive and safe approach. neuroaxial anesthesia procedures can be conducted using two different ultrasound techniques; real-time ultrasound guided (usrtg) and ultrasound-assisted (usas). the primary objective of this study is to compare the successes of spinal anesthesia applications using usrtg, usas, and conventional landmark techniques on the first attempt in obese patients undergoing orthopedic surgery.

patients included in the study will be those undergoing lower extremity orthopedic surgery, with a body mass index (bmi) 30 kg/m² and above, and classified as american society of anesthesiologists (asa) class i-iii. patients will be randomized into 3 groups. in the conventional landmark group, spinal anesthesia will be administered using the conventional technique. in the ultrasound-assisted group, the spinal space will be marked with ultrasound before proceeding. for the real-time ultrasound-guided group, the spinal space and the advancement of the needle for the injection will be visualized simultaneously with ultrasound during the application of spinal anesthesia. the primary outcome is to compare the success rates on the first attempt. the secondary outcomes are to compare the number of skin punctures, needle redirections, procedure times, complications, and patient satisfaction

Eligibility criteria:
inclusion criteria: * 18 years and older * patients who will undergo lower extremity orthopedic surgery * asa i-ii-iii patients * bmi 30 kg/m² and above exclusion criteria: * bmi \< 30 kg/m² * asa iv-v patients * severe cardiovascular disease * patients with a known or suspected allergy to local anesthetics * contraindications of spinal anesthesia (eg, coagulopathy, puncture site infection)

Keywords: anesthesia spinal anesthesia obesity ultrasonography
enteral nutrition in acute generalized peritonitis

Conditions: Enteral and Supplement Feeds Adverse Reaction; Peritonitis; Acute

Summary: hospitals in south kivu always have problems supplying artificial enteral nutritional products because of their high cost and low availability in our areas. while the province has cereals, knowing their nutritional composition would enable the formulation of a nutritional product based on local protein-energy products. hence the questions below: can a local cereal-based protein-energy ration be used instead of a costly imported artificial nutritional solution to improve the nutritional status of patients operated on for pag? what is the tolerance of this early enteral nutrition on the healing and functional recovery of patients compared with an artificial nutritional solution? to answer these questions, a randomized clinical trial has been designed with the following objectives: * to formulate an enteral diet using cereals available in our environment with a protein-calorie composition superimposable on the artificial enteral ration, * evaluate the tolerance and advantages of early enteral nutrition with a locally manufactured protein-caloric ration vs. a commercially available artificial nutritional solution in patients undergoing surgery for pag.


Eligibility criteria:
inclusion criteria: * patient operated for peritonitis with intestinal suture during treatment * have a q-sofa score of 1 to 2 * surgeon's agreement to enteral feeding * at risk of malnutrition (bmc) exclusion criteria: * q sofa score \> 2 * patients with tare (diabetes, hiv, renal failure)
the effect of n-3 fatty acid supplementation on serum levels, and gene expression of type2 diabetes patient

Conditions: Diabetes Mellitus Type II

Summary: the aim of this study is to determine the effects of supplementation with n-3 fatty acid or placebo for 10 weeks on the expression of sirt-1, adipor1 \& adipor2 genes in the peripheral blood mononuclear cell (pbmc) and circulatory levels of resistin, mcp-1 and adiponectin of type2 diabetes patient

the aim of this study is to determine of the effects of supplementation with n-3 fatty acid or placebo for 10 weeks on the expression of sirt-1, adipor1(adiponectin receptor 1) \& adipor2 (adiponectin receptor 2) genes in the peripheral blood mononuclear cell (pbmc) and circulatory levels of resistin, mcp-1 (monocyte chemoattractant protein-1) and adiponectin of type2 diabetes patient. in this randomized, double-blind clinical trial, placebo-controlled, 88 men and women with type 2 diabetes are enrolled in the study from the iranian diabetes association. after signing informed consent all individuals complete a general information form , 24-hour food recall for 3 days and beck depression questionnaire will be taken from the participants at the beginning and the end of the study. selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo. the supplement group, will receive mg 1800mg epa(eicosapentaenoic acid ) \& 900mg dha( docosahexaenoic acid) (total=2700mg) for 10 weeks and the placebo group will also receive placebo (containing 2700 mg of edible paraffin) (similar in terms of color, shape and size). patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity. blood samples will be collected after 12 hours fasting and anthropometric variables, biochemical parameters, target gene expression and physical activity before and after the trial will be measured

Eligibility criteria:
inclusion criteria: * willingness to participation, * diabetic patients 30- 60 years old, * body mass index in the range 25-40, * avoidance of dietary supplements, * vitamins and herbal products at least 3 months before and throughout the intervention exclusion criteria: * people who have used n-3 fatty acid supplementation in last 3 months, * having chronic renal disease , * gi disease, * hepatobiliary diseases, * hematological disorders, * hypo- or hyperthyroidism, * type 1 diabetes, * treatment with orlistat or sibutramine for weight loss, * pregnancy and lactation, * treatment with insulin or thiazolidinediones.

Keywords: n-3 fatty acid sirt-1 adipor1 adipor2 mcp-1 adiponectin resistin t2dm
iron indices and intravenous ferumoxytol: time to steady state

Conditions: Iron Deficiency Anemia

Summary: the purpose of this study is to evaluate the time point of transferrin saturation (tsat) and ferritin stabilization after a thirteen-treatment period following a ferumoxytol load, as well as to determine the point at which serum ferritin and tsat concentrations can be checked in iron deficiency anemia (ida) hemodialysis patients.


Eligibility criteria:
inclusion criteria: * chronic hemodialysis subjects who have received dialysis treatment for more than 90 days * tsat less than or equal to 25 percent * serum ferritin less than or equal to 200 nanograms/milliliter (ng/ml) * (female) subjects are willing to use reliable contraception, or have undergone menopause (chemical or surgical) * subjects who are able to read and write in english * subjects who have signed consent exclusion criteria: * subjects who have been enrolled in a clinical trial within the past 30 days * subjects who have received iv iron within 4 weeks of the start of the study * serum ferritin greater than or equal to 1200 ng/dl * hemoglobin (hb) less than 10 grams/deciliter (g/dl), or greater than 13.5 g/dl * evidence of iron overload * known hypersensitivity to ferumoxytol or any of its components * anemia caused by conditions other than iron deficiency * subjects with elective surgeries scheduled within the next 3 months * subjects with elective magnetic resonance procedure scheduled during the study period * subjects who have been hospitalized within the past 30 days (excluding vascular access care) * subjects who have received a blood transfusion in the past 30 days * subjects who are transfusion dependent * (female) subjects who are pregnant or nursing * subjects with known inflammatory conditions which may affect serum ferritin * subjects who are considered to be clinically unstable at the discretion of principal investigator (p.i.) * subjects who have a clinically unstable blood pressure (bp) of systolic greater than 180 millimeters of mercury (mmhg) and/or diastolic greater than 100 mmhg (sitting, pre-dialysis) * subjects with life expectancy less than 6 months * subjects who refuse to sign consent
postoperative pain and blood loss of non-use compared to partial-use of a tourniquet in bilateral total knee replacement

Conditions: Pain, Postoperative; Total Knee Replacement; Tourniquet

Summary: postoperative pain and blood loss of non-use compared to partial-use of a tourniquet in bilateral total knee replacement: a randomized- control trial this study aimed to compare the effects of non-use (ntu) and partial-use (before osteotomy to skin closure; boo) of a tourniquet in bilateral total knee arthroplasty (tka) on postoperative pain and complications.

despite numerous meta-analyses, and randomized-control trials (rcts), there is still no conclusive evidence on the most effective, and efficient method of using a tourniquet. there is gap of knowledge of method of tourniquet usage. hence this study will provide the best method to apply tourniquet.

Eligibility criteria:
inclusion criteria: * patients with over 50 years of age and diagnosed with bilateral severe knee osteoarthritis undergoing bilateral tka exclusion criteria: * patients having undergone previous knee surgery * patients being subject to uncontrolled hypertension, coagulopathy, or recent knee sepsis * patients with an asa physical status grade \> 2, * inability to use patient-controlled analgesia (pca), such as communication, or cognitive issues, or those patients who were allergic to medications used in the treatment process.